Trial Profile

A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients

Status: Discontinued

Phase of Trial: Phase 0

Latest Information Update: 02 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Isatuximab (Primary)
Indications Haematological malignancies
Focus Pharmacodynamics
Acronyms SuppCare 001

Most Recent Events

31 Jul 2024 Status changed from recruiting to discontinued.
03 Aug 2023 Planned End Date changed from 1 Jul 2025 to 1 Jan 2027.
03 Aug 2023 Planned primary completion date changed from 15 Jul 2023 to 15 Jan 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com